hit counter

Vraylar (Cariprazine) Approved For Schizophrenia & Bipolar Disorder

Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder.  In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient.  The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …

Read more

Rexulti (Brexpiprazole) Approved For Schizophrenia & Depression (Adjunct)

Rexulti (Brexpiprazole) is a drug that was approved July 10, 2015 for the treatment of schizophrenia and as an adjunctive option for major depressive disorder.  In clinical trials it was referred to as the chemical “OPC-34712” and is being marketed as a superior successor to Abilify (Aripiprazole) due to the fact that Abilify’s patent expired …

Read more

Spadin (Peptide) For Depression: A TREK-1 Inhibitor Antidepressant

Depression is a growing epidemic that affects the lives of nearly 15 million Americans.  The number of individuals diagnosed with depression will continue to grow as a result of population growth, poor diet, environmental toxins, genetic polymorphisms, and other unique neurophysiological factors.  As a result of depression, it is estimated that nearly 1 out of …

Read more

Eating A Ketogenic Diet For Epilepsy & Seizure Reduction

A ketogenic diet involves consumption of foods with high fat (80%), moderate protein (15%), and low carbohydrates (5%).  Consistent intake of high fat, moderate protein foods, with simultaneous avoidance of carbohydrates, allows the body to transition from using glucose (sugar) as a primary source of fuel, to using ketone bodies (commonly called “ketones”).  During ketosis, …

Read more